Blog

ViiV, Janssen’s two-drug HIV regimen hits PhIII targets

[From Pharma Times, August 15, 2018]

“ViiV Healthcare and Janssen have unveiled positive headline data from a late-stage trial of their injectable two-drug regimen for the treatment of HIV.”

For more, click here.